BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18172298)

  • 21. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
    Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
    Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
    Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB
    Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
    Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
    Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
    Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
    APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ETS fusion genes in prostate cancer.
    Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
    Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 30. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
    Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
    Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.
    Hermans KG; van der Korput HA; van Marion R; van de Wijngaart DJ; Ziel-van der Made A; Dits NF; Boormans JL; van der Kwast TH; van Dekken H; Bangma CH; Korsten H; Kraaij R; Jenster G; Trapman J
    Cancer Res; 2008 Sep; 68(18):7541-9. PubMed ID: 18794142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China.
    Wang JJ; Liu YX; Wang W; Yan W; Zheng YP; Qiao LD; Liu D; Chen S
    Asian Pac J Cancer Prev; 2012; 13(10):4935-8. PubMed ID: 23244085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
    Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
    Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of ETV1, ETV4 and ETV5 RNA in-situ hybridization in the diagnosis of CIC-DUX sarcomas.
    Smith SC; Palanisamy N; Martin E; Almenara J; McHugh JB; Choi EK; Lucas DR; Betz BL; Thomas D; Patel RM
    Histopathology; 2017 Mar; 70(4):657-663. PubMed ID: 27790742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
    Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.
    Torres A; Alshalalfa M; Tomlins SA; Erho N; Gibb EA; Chelliserry J; Lim L; Lam LLC; Faraj SF; Bezerra SM; Davicioni E; Yousefi K; Ross AE; Netto GJ; Schaeffer EM; Lotan TL
    J Mol Diagn; 2017 May; 19(3):475-484. PubMed ID: 28341589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.